These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Antibiotics and outcomes of CF pulmonary exacerbations in children infected with MRSA and Pseudomonas aeruginosa. Cogen JD; Hall M; Faino AV; Ambroggio L; Blaschke AJ; Brogan TV; Cotter JM; Gibson RL; Grijalva CG; Hersh AL; Lipsett SC; Shah SS; Shapiro DJ; Neuman MI; Gerber JS J Cyst Fibros; 2023 Mar; 22(2):313-319. PubMed ID: 35945130 [TBL] [Abstract][Full Text] [Related]
3. Association Between Number of Intravenous Antipseudomonal Antibiotics and Clinical Outcomes of Pediatric Cystic Fibrosis Pulmonary Exacerbations. Cogen JD; Faino AV; Onchiri F; Hoffman LR; Kronman MP; Nichols DP; Rosenfeld M; Gibson RL Clin Infect Dis; 2021 Nov; 73(9):1589-1596. PubMed ID: 34100912 [TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes of Antipseudomonal versus Other Antibiotics among Children with Cystic Fibrosis without Cogen JD; Faino AV; Onchiri F; Gibson RL; Hoffman LR; Nichols DP; Rosenfeld M; Kronman MP Ann Am Thorac Soc; 2022 Aug; 19(8):1320-1327. PubMed ID: 35289740 [No Abstract] [Full Text] [Related]
6. Systemic Corticosteroids in the Management of Pediatric Cystic Fibrosis Pulmonary Exacerbations. Davis CS; Faino AV; Onchiri F; Gibson RL; Merjaneh L; Ramsey BW; Rosenfeld M; Cogen JD Ann Am Thorac Soc; 2023 Jan; 20(1):75-82. PubMed ID: 36044723 [No Abstract] [Full Text] [Related]
7. Association of Inhaled Antibiotics in Addition to Standard Intravenous Therapy and Outcomes of Pediatric Inpatient Pulmonary Exacerbations. Cogen JD; Faino AV; Onchiri F; Hoffman LR; Kronman MP; Nelson M; Nichols DP; Rosenfeld M; VanDevanter DR; Gibson RL Ann Am Thorac Soc; 2020 Dec; 17(12):1590-1598. PubMed ID: 32726564 [No Abstract] [Full Text] [Related]
8. Outcomes of cystic fibrosis pulmonary exacerbations treated with antibiotics with activity against anaerobic bacteria. Castner LM; Zimbric M; Cahalan S; Powell C; Caverly LJ J Cyst Fibros; 2021 Nov; 20(6):926-931. PubMed ID: 33612403 [TBL] [Abstract][Full Text] [Related]
9. Effect of Concomitant Azithromycin and Tobramycin Use on Cystic Fibrosis Pulmonary Exacerbation Treatment. Cogen JD; Faino AV; Onchiri F; Gibson RL; Hoffman LR; Kronman MP; Rosenfeld M; Nichols DP Ann Am Thorac Soc; 2021 Feb; 18(2):266-272. PubMed ID: 32810412 [No Abstract] [Full Text] [Related]
10. Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis. Hoppe JE; Wagner BD; Accurso FJ; Zemanick ET; Sagel SD J Cyst Fibros; 2018 Nov; 17(6):760-768. PubMed ID: 29921503 [TBL] [Abstract][Full Text] [Related]
11. Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations. Thornton CS; Caverly LJ; Kalikin LM; Carmody LA; McClellan S; LeBar W; Sanders DB; West NE; Goss CH; Flume PA; Heltshe SL; VanDevanter DR; LiPuma JJ Ann Am Thorac Soc; 2024 Apr; 21(4):595-603. PubMed ID: 37963297 [No Abstract] [Full Text] [Related]
12. Changes in airway bacterial communities occur soon after initiation of antibiotic treatment of pulmonary exacerbations in cystic fibrosis. Carmody LA; Kalikin LM; VanDevanter DR; Li G; Opron K; Simon RH; Caverly LJ; LiPuma JJ J Cyst Fibros; 2022 Sep; 21(5):766-768. PubMed ID: 35667975 [TBL] [Abstract][Full Text] [Related]
13. Oral antibiotic prescribing patterns for treatment of pulmonary exacerbations in two large pediatric CF centers. Hoppe JE; Hinds DM; Colborg A; Wagner BD; Morgan WJ; Rosenfeld M; Zemanick ET; Sanders DB Pediatr Pulmonol; 2020 Dec; 55(12):3400-3406. PubMed ID: 32970375 [TBL] [Abstract][Full Text] [Related]
14. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site. Schechter MS; Regelmann WE; Sawicki GS; Rasouliyan L; VanDevanter DR; Rosenfeld M; Pasta D; Morgan W; Konstan MW Pediatr Pulmonol; 2015 May; 50(5):431-40. PubMed ID: 25530325 [TBL] [Abstract][Full Text] [Related]
15. Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response. Lam JC; Somayaji R; Surette MG; Rabin HR; Parkins MD BMC Infect Dis; 2015 Mar; 15():145. PubMed ID: 25887462 [TBL] [Abstract][Full Text] [Related]
16. Cystic Fibrosis Pulmonary Exacerbations Attributable to Respiratory Syncytial Virus and Influenza: A Population-Based Study. Somayaji R; Goss CH; Khan U; Neradilek M; Neuzil KM; Ortiz JR Clin Infect Dis; 2017 Jun; 64(12):1760-1767. PubMed ID: 28329304 [TBL] [Abstract][Full Text] [Related]
17. Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis. Hoppe JE; Wagner BD; Sagel SD; Accurso FJ; Zemanick ET BMC Pulm Med; 2017 Dec; 17(1):188. PubMed ID: 29228933 [TBL] [Abstract][Full Text] [Related]
18. Clinical features associated with pulmonary exacerbation diagnosis in infants and young children with cystic fibrosis. Corcoran A; Faig W; Ren CL Pediatr Pulmonol; 2024 Apr; 59(4):874-879. PubMed ID: 38131505 [TBL] [Abstract][Full Text] [Related]
19. Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF. Heltshe SL; West NE; VanDevanter DR; Sanders DB; Beckett VV; Flume PA; Goss CH; Contemp Clin Trials; 2018 Jan; 64():35-40. PubMed ID: 29170074 [TBL] [Abstract][Full Text] [Related]
20. Evaluating FEV1 decline in diagnosis and management of pulmonary exacerbations in children with cystic fibrosis. Bouzek DC; Ren CL; Thompson M; Slaven JE; Sanders DB Pediatr Pulmonol; 2022 Jul; 57(7):1709-1716. PubMed ID: 35429154 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]